Brexpiprazole: At the Crossroads of Neuropsychiatric Symptoms
Tracking # 20-1364708
Course overview
Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults, as well as the treatment of schizophrenia in patients aged 13 years and older. In 2023, the FDA approved the original form of brexiprazole for the treatment of agitation symptoms associated with dementia due to Alzheimers Disease. Brexpiprazole may also have promise in the treatment of unipolar and bipolar patients with treatment-resistant depression when used in combination with other drugs. Notable adverse effects include akathisia and weight gain. Data is limited comparing brexpiprazole to other antipsychotics, but it should be considered in patients who have not tolerated other antipsychotics well.
Subject areas
This course counts toward the state boards and subject areas below.